Burn News and Research

RSS

NHS makeover not welcomed by the BMA

The British Medical Association (BMA) has expressed doubts about the radical makeover of the NHS and how it would affect patient care. The reorganization of the NHS in England was unveiled in health secretary Andrew Lansley's white paper in July. The BMA says that the plans are potentially damaging, risk setting groups of clinicians against each other and are not a good use of public money when the NHS has to save £15 to £20 billion.

1 Oct 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

IsoRay reports increase revenue for 2010 fiscal year

IsoRay Inc. a medical isotope company and the exclusive manufacturer of Cesium-131 used in internal radiation therapy for the treatment of lung, colon, head and neck, and prostate cancers, ocular melanoma, and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the year ended June 30, 2010.

28 Sep 2010

Optogenetics helps to restore optimal movement in people with physical disabilities

Researchers at Stanford University were able to use light to induce normal patterns of muscle contraction, in a study involving bioengineered mice whose nerve-cell surfaces are coated with special light-sensitive proteins.

28 Sep 2010

Viridis BioPharma receives approval to manufacture, market NIMBUS antimicrobial technology in India

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that its proprietary NIMBUS antimicrobial technology has been approved for manufacture, marketing and sale in India. Viridis BioPharma, an India-based manufacturer and marketer of medical devices, received approval by the Food and Drug Administration of India to manufacture and market gauze wound dressings that incorporate NIMBUS antimicrobial technology.

28 Sep 2010

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

DecImmune Therapeutics announced today that it has received a $1 million equity investment from Astellas Venture Management and has additionally been awarded $2.2 million in Phase II SBIR funding from the National Institutes of Health.

28 Sep 2010

UCLA develops educational program to train U.S. armed forces in critical combat casualty care

With American troops leaving Iraq and military efforts continuing in Afghanistan, UCLA has helped develop a first-of-its-kind educational program to train U.S. armed forces medical personnel in critical combat casualty care. The program will not only help advance military care, the program's developers say, but civilian care as well.

27 Sep 2010

FDA grants ArthroCare marketing clearance for Parallax Contour Vertebral Augmentation Device

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Parallax® Contour® Vertebral Augmentation Device (Contour) specifically for void creation in a vertebral body followed by injection of bone cement. Vertebral body void creation followed by bone cement augmentation is commonly used to treat painful vertebral compression fractures.

24 Sep 2010

Progress in realizing potential of satellite measurements of air pollution

In many developing countries, the absence of surface-based air pollution sensors makes it difficult, and in some cases impossible, to get even a rough estimate of the abundance of a subcategory of airborne particles that epidemiologists suspect contributes to millions of premature deaths each year. The problematic particles, called fine particulate matter (PM2.5), are 2.5 micrometers or less in diameter, about a tenth the fraction of human hair. These small particles can get past the body's normal defenses and penetrate deep into the lungs.

24 Sep 2010

George Higginson Professor to receive 2010 Warren Alpert Foundation Prize

Howard Green, a founding father of regenerative medicine and the George Higginson Professor of Cell Biology at Harvard Medical School, will receive the 2010 Warren Alpert Foundation Prize for developing methodologies leading directly to permanent skin restoration therapy which is saving the lives of thousands of burn patients around the world.

22 Sep 2010

Access enters $30M supply agreement for MuGard with RHEI

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.

21 Sep 2010

Access Pharmaceuticals launches product website for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.

15 Sep 2010

BioCryst reports results from forodesine studies for CTCL and CLL

BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).

15 Sep 2010

Lippincott Williams & Wilkins enter into licensing agreement with CJAPS to provide PRS journal in Chinese

Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health, is pleased to announce that it has entered into a licensing agreement with the Chinese Journal of Aesthetic and Plastic Surgery (CJAPS), to provide selected articles and abstracts from Plastic and Reconstructive Surgery (PRS), the official journal of the American Society of Plastic Surgeons, to be translated into Chinese and published in CJAPS.

15 Sep 2010

Genmab announces update in corporate strategy

Genmab A/S announced today an update to its corporate strategy. Today's strategy update represents a new beginning for Genmab where we acknowledge our successes and learn from our mistakes.

14 Sep 2010

U.S. adults support restrictions on e-cigarettes based on potential risks

According to the makers of electronic cigarettes, they are new devices that allow users to inhale nicotine but not the toxins of tobacco cigarettes. Advocates hail e-cigarettes as a possible quit-smoking aid.

14 Sep 2010

Leukemia survivor to meet donor of bone marrow transplant

Ann Marie Del Fiacco, a 38-year-old Berwyn mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant.

13 Sep 2010

Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

Purdue Pharma L.P. will present data from the clinical program for Butrans™ (buprenorphine) Transdermal System CIII in a series of posters at PAINWeek®2010, September 8-10 in Las Vegas.

10 Sep 2010

VCU Pauley Heart Center to investigate portable, mechanical driver for powering artificial hearts

The Virginia Commonwealth University Medical Center is the lead institution in a national clinical trial of technology that will allow artificial heart patients to recuperate, rehabilitate and wait in the comfort of their own homes until a donor heart becomes available for transplant.

10 Sep 2010

Burn News and Research

NHS makeover not welcomed by the BMA

Cardium expands wound healing and tissue regeneration portfolio

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

IsoRay reports increase revenue for 2010 fiscal year

Optogenetics helps to restore optimal movement in people with physical disabilities

Viridis BioPharma receives approval to manufacture, market NIMBUS antimicrobial technology in India

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

UCLA develops educational program to train U.S. armed forces in critical combat casualty care

FDA grants ArthroCare marketing clearance for Parallax Contour Vertebral Augmentation Device

Progress in realizing potential of satellite measurements of air pollution

George Higginson Professor to receive 2010 Warren Alpert Foundation Prize

Access enters $30M supply agreement for MuGard with RHEI

Access Pharmaceuticals launches product website for MuGard

BioCryst reports results from forodesine studies for CTCL and CLL

Lippincott Williams & Wilkins enter into licensing agreement with CJAPS to provide PRS journal in Chinese

Genmab announces update in corporate strategy

U.S. adults support restrictions on e-cigarettes based on potential risks

Leukemia survivor to meet donor of bone marrow transplant

Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

VCU Pauley Heart Center to investigate portable, mechanical driver for powering artificial hearts

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News